

NeuroMetrix, Inc. (NASDAQ: NURO)

NEWS MEDIA FACT SHEET

NeuroMetrix is an established medical device company building a focus on the neurological complications of diabetes. A market pioneer in point-of-care nerve testing, **NeuroMetrix** is using its expertise in neurophysiology to address an unmet global need in diabetic neuropathy.

MARKETS

A market leader in neurodiagnostics, **NeuroMetrix** reorganized in late 2010 to focus on the growth market of diabetic neuropathy, its detection, care, and treatment. Recent studies indicate that there are over 300 million people with diabetes in the world. The most common complication of diabetes is diabetic peripheral neuropathy (DPN). DPN is a degeneration of nerves throughout the body, first and most severely, in the feet. The nerve damage leads to sensory loss which may trigger foot ulcers that require amputation. Another manifestation of the nerve pathology is severe pain that is highly disabling. According to the Centers for Disease Control, over 50% of people with diabetes have DPN and the annual cost of treating DPN has been estimated as high \$14B in the United States alone.

PRODUCTS & BUSINESS

NeuroMetrix has two products on the market: **ADVANCE™ NCS/EMG** and **NC-stat® DPNCheck™**



ADVANCE NCS/EMG System is **NeuroMetrix's** original business, a platform for performing nerve conduction studies (NCS) and electromyography (EMG) procedures. Using **ADVANCE**, a physician can run traditional nerve tests, get immediate results, and prepare thorough test reports. The technology simplifies testing and reporting, thereby expediting diagnosis and improving patient care for indications like diabetic neuropathy, low back pain, and carpal tunnel syndrome.

NC-stat DPNCheck, **NeuroMetrix's** latest product offering, is a handheld device built on the same principles as **ADVANCE** that may aid in the early detection, confirmation, and monitoring of DPN. This device, a modified version of the widely-used NC-stat® system, measures sural nerve conduction velocity and response amplitude, which are standard biomarkers for DPN. Currently available testing methods at the point-of-care are subjective and can only detect late state DPN, when it may be too late for effective treatment.

NC-stat DPNCheck allows for early detection of the disorder. It uses single-patient biosensors and provides data that is straightforward to interpret. **NC-stat DPNCheck** was launched in June 2011 at the American Diabetes Association 71st Scientific Sessions.





R&D PIPELINE

In 2011, following the launch of **NC-stat DPNCheck**, **NeuroMetrix** announced that it is developing a new product called **SENSUS™**. The device is a wearable nerve stimulator, used in the management of chronic pain, such as that caused by DPN. A 510(k) is expected to be filed in 2Q 2012, with commercial launch anticipated towards the end of 2012.

Earlier in the R&D pipeline, NeuroMetrix is in the assessment stage on a point-of-care autonomic neuropathy test, **ANCheck™**, and a sensory assist device for advanced neuropathy, **Sentinel™**.

MANAGEMENT

Shai N. Gozani, M.D., Ph.D.

President, Chief Executive Officer and Director

Dr. Gozani founded NeuroMetrix in 1996 and currently serves as Chairman of the board of directors and as President and Chief Executive Officer. Prior to forming the company, Dr. Gozani completed a neurophysiology research fellowship in the laboratory of Dr. Gerald Fischbach at Harvard Medical School. Dr. Gozani holds a B.A. degree in Computer Science, an M.S. degree in Biomedical Engineering and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.



Dr. Shai Gozani (left) & Tom Higgins (right)

Thomas T. Higgins

Senior Vice President and Chief Financial Officer

Mr. Higgins has a broad set of financial management and operations skills from his experience with publicly traded companies in life sciences, specialty chemicals and financial services. He has extensive international experience with a particular emphasis on Japan, Southeast Asia and the Middle East. Prior to joining NeuroMetrix, Mr. Higgins was Executive Vice President and Chief Financial Officer at Caliper Life Sciences Inc, a provider of technology and services for life sciences research. Before Caliper, Mr. Higgins was Executive Vice President, Operations and Chief Financial Officer at V.I. Technologies, Inc. ("Vitex"), a biotechnology company addressing blood safety. Before Vitex, Mr. Higgins served at Cabot Corporation in various senior finance and operations roles. His last position at Cabot was President of Distrigas of Massachusetts Corporation, a subsidiary involved in the liquefied natural gas business, and prior to that he was responsible for Cabot's Asia Pacific carbon black operations. Before joining Cabot, Mr. Higgins began his career with Price Waterhouse. Mr. Higgins holds a B.B.A. with honors from Boston University.

CONTACT

Mr. Thomas Higgins
Chief Financial Officer
NeuroMetrix
62 4th Avenue
Waltham, MA 02451 USA
www.neurometrix.com